The European Association for the Study of the Liver (EASL) Congress was held in Amsterdam, the Netherlands on 7-10 May 2025. Check out the official website of the Congress.
Here is selected coverage on viral hepatitis:
Hepatitis B:
- Arbutus presents clinical trial data from its two HBV assets, imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 /press release/
- Virion Therapeutics reports new data from two clinical presentations at EASL 2025, including rapid and profound hepatitis B surface antigen declines with the first VRON-0200 containing combination therapy for HBV functional cure /press release/
- Precision BioSciences announces presentation of initial safety data from the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL) /press release/
- AusperBio presents interim Phase IIb AHB-137 clinical data in a late-breaking abstract at EASL™ Congress 2025 /press release/
- Vir Biotechnology announces preliminary 24-week post-end of treatment data for tobevibart and elebsiran combinations in chronic hepatitis B from the MARCH study /press release/
— SEE ALSO: Contagion Live: Vir Biotechnology announces results of its potential hepatitis B cure combination therapy
- Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 /press release/
- Brii Bio presents late-breaking data from its ongoing Phase 2 ENSURE study at EASL Congress 2025, suggesting BRII-179’s role in advancing higher HBsAg loss /press release/
- Contagion Live: Novel hepatitis B vaccines show promise in Phase 1a study: Safety and immunogenicity results for GS-2829 and GS-6779
Hepatitis D:
- New preclinical data for Assembly Biosciences’ oral hepatitis D virus entry inhibitor ABI-6250 and next-generation hepatitis B virus capsid assembly modulator ABI-4334 presented at the EASL Congress 2025 /press release/
- Gilead Sciences: Final data from the Phase 3 MYR301 study demonstrated longer treatment with bulevirtide was associated with sustaining undetectability after stopping treatment /press release/
— SEE ALSO: Pharmaceutical Executive: Gilead’s entry inhibitor for chronic hepatitis delta demonstrates durable virologic suppression post-treatment
— SEE ALSO: Contagion Live: Gilead’s bulevirtide demonstrates long-term sustained virologic response for hepatitis D
— SEE ALSO: Contagion Live: Hepatitis D patients maintain undetectable virus nearly 2 years after bulevirtide therapy
Hepatitis C:
— SEE ALSO: Drug Topics: Bemnifosbuvir, ruzasvir regimen shows strong efficacy as HCV treatment
— SEE ALSO: Contagion Live: HCV therapy demonstrates 98% sustained virologic response at 12 weeks post treatment
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.